Tang Capital Management’s Aligos Therapeutics ALGS Stock Holding History

Tang Capital Management’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-141,131	Closed	-$1.02M	–	195
2025 Q2	$1.02M	Hold	141,131	–	–	0.05%	152
2025 Q1	$1.16M	Buy	+141,131	New	+$3.09M	0.06%	145
2024 Q3	–	Sell	-66,000	Closed	-$578K	–	156
2024 Q2	$578K	Hold	66,000	–	–	0.06%	104
2024 Q1	$1.62M	Sell	66,000 -21,594	-25%	-$430K	0.17%	80
2023 Q4	$1.45M	Sell	87,594 -45,568	-34%	-$783K	0.13%	99
2023 Q3	$2.49M	Hold	133,162	–	–	0.35%	65
2023 Q2	$3.23M	Sell	133,162 -3,830	-3%	-$103K	0.48%	58
2023 Q1	$2.99M	Buy	136,992 +24,336	+22%	+$930K	0.45%	53
2022 Q4	$2.68M	Buy	112,656 +45,689	+68%	+$1.15M	0.39%	56
2022 Q3	$1.84M	Buy	66,967 +5,059	+8%	+$168K	0.23%	72
2022 Q2	$1.87M	Buy	+61,908	New	+$2.1M	0.28%	52

Other funds holding ALGS

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

RAM

Readystate Asset Management Chicago, Illinois $2.23B AUM 15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Tang Capital Management's ALGS Position: Q3 2025 in Review

Tang Capital Management sold out of Aligos Therapeutics (ALGS) in Q3 2025, closing a stake of 141,131 shares — an estimated $1.02M sold.

Tang Capital Management first reported a position in ALGS in Q2 2022 and held it in 11 quarters. The position peaked at $3.23M in Q2 2023. 33 funds tracked by Wall St. Rank hold ALGS as of Q3 2025.

Tang Capital Management reported no remaining Aligos Therapeutics position as of Q3 2025 after selling out during the quarter.
Tang Capital Management sold 141,131 Aligos Therapeutics shares in Q3 2025, an estimated $1.02M.
Tang Capital Management first reported a position in Aligos Therapeutics in Q2 2022 and held it in 11 quarters.
Tang Capital Management's Aligos Therapeutics position peaked at $3.23M in Q2 2023.
33 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q3 2025.

Based on Tang Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.